Navigation Links
Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
Date:2/12/2008

ose in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2007 and the quarterly report on Form 10-Q for the quarter ended October 31, 2007. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

Contacts:

GendeLLindheim BioCom Partners

Investors Media

info@peregrineinc.com Jennifer Anderson

(800) 987-8256 (212) 918-4642


'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
2. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
3. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
6. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Access Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
9. XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
10. Koronis Pharmaceuticals Appoints David Drajeske Director of Business Development
11. Onyx Pharmaceuticals to Present at BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... MA, San Antonio, TX (PRWEB) August 29, 2014 ... ISO 9001:2008 and ISO 13485:2003 certified, GAMP® 5 ... has been awarded an international Phase II clinical ... with non-Hodgkin’s lymphoma. , Throughout this trial, Intrinsic ... including, but not limited to, protocol and charter ...
(Date:8/28/2014)... research platform uses a laser to measure ... stress and heating, an approach likely to ... and batteries., This new technique, called nanomechanical ... and the surface stress of microscale structures ... the merits of surface-stress influence on mechanical ...
(Date:8/28/2014)... SunTrust Robinson Humphrey (STRH) today announced the ... research team in biotechnology and oilfield services.  ... demonstrates our commitment to providing our valued institutional ... decision making," said Biff Woodruff , Head ... significant investments in differentiated content at a time ...
(Date:8/28/2014)... Woodstock, Vt. (PRWEB) August 28, 2014 ... microbiology testing around the world is available from ... industrial diagnostics companies. “ Industrial Microbiology Market Review, ... the Industrial Market ” (IMMR—4) tracks and compares ... in in North America, Europe and Asia, and ...
Breaking Biology Technology:Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2New analytical technology reveals 'nanomechanical' surface traits 2New analytical technology reveals 'nanomechanical' surface traits 3SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 2SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 32 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 22 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 3
... July 15 Amsterdam,Molecular Therapeutics (Euronext: AMT), a ... announced the start of a collaboration with St. ... the development,of a gene therapy treatment for Hemophilia ... commercial rights to the final product. The,combination of ...
... A report published in the July 8 issue of ... Sciences ( PNAS ) is the first to ... of tiny nanoclusters of metallic gold. The study, which ... the work of researchers at four universities on two ...
... HealthSonix, Inc.,(Pink Sheets: HSXI)(FWB:H7S) today announced that ... purchased two wholly owned,subsidiaries of HealthSonix, Inc. ... "Selling the two operating companies to Innovative ... the companies to,resume full operations and get ...
Cached Biology Technology:AMT Starts Collaboration With St. Jude Children's Research Hospital on Gene Therapy for Hemophilia B. Company Accesses Exclusive Commercial Rights to Final Therapy 2AMT Starts Collaboration With St. Jude Children's Research Hospital on Gene Therapy for Hemophilia B. Company Accesses Exclusive Commercial Rights to Final Therapy 3AMT Starts Collaboration With St. Jude Children's Research Hospital on Gene Therapy for Hemophilia B. Company Accesses Exclusive Commercial Rights to Final Therapy 4Study reveals principles behind stability and electronic properties of gold nanoclusters 2Study reveals principles behind stability and electronic properties of gold nanoclusters 3Study reveals principles behind stability and electronic properties of gold nanoclusters 4HealthSonix Sells Operating Subsidiaries to Innovative Health Sciences 2
(Date:8/28/2014)... MD FASEB MARC (Maximizing Access to Research ... for the American College of Sports Medicine,s Conference ... 2014 in Miami, Florida. These awards are ... doctorates and scientists from underrepresented groups into the ... encourage the participation of young scientists at the ...
(Date:8/28/2014)... PA, August 28, 2014 Dyslexia, the most ... is a neurological reading disability that occurs when ... language don,t function normally. , The use of ... brain activity is disrupted in dyslexia. However, most ... number of brain regions, leaving a gap in ...
(Date:8/28/2014)... and mould in homes could pose a significant health risk ... in the Journal of Allergy and Clinical Immunology . ... eight different countries, the research has found that the presence ... in asthma sufferers, as well as increasing the likelihood of ... a team at the University of Exeter Medical School and ...
Breaking Biology News(10 mins):Dyslexic readers have disrupted network connections in the brain 2Indoor mold poses health risk to asthma sufferers 2
... HOUSTON -- (Aug. 16, 2010) -- A new ... and other human activity has completely obscured the natural ... "The natural factors that influence carbon dioxide cycling ... the radiocarbon signature of the river to reflect those ...
... of some of the most repugnant smells on earth, but ... has a sense of smell of its own. A team ... first time that bacteria have a molecular "nose" that is ... today in Biotechnology Journal , their study shows how ...
... infrared laser can make a heart beat faster. Scientists ... pulsed light can pace contractions in an avian embryonic heart, ... pacing of the embryonic heart," will be published in the ... 15, 2010. According to the scientists, this non-invasive device ...
Cached Biology News:A river flipped: Humans trump nature on Texas river 2A river flipped: Humans trump nature on Texas river 3Bacteria breakthrough is heaven scent 2A heart beats to a different drummer 2
... BODIPY FL ATP-Gamma-S binds to ... nucleotide the BODIPY FL fluorophore was ... In addition to its potential use ... ATP-Gamma-S thioether is an important new ...
... world of discovery races ever faster, you need ... fast track. So our constant focus is on ... research. Thats why our Biomek 3000 Laboratory Automation ... advanced as it is flexible. By integrating all ...
... Pro is the industry standard microarray image ... of imaging and analysis tools, visualizations, automation ... Pro is included with every GenePix scanner, ... third-party scanners and all types of arrays. ...
... 60 rabbit tissue samples arrayed on Superfrost Plus ... and 1 hematoxylin and eosin (H&E) stained slide ... tissues from 4 rabbit organisms, for a total ... sample (or core) is 1.5 mm in diameter. ...
Biology Products: